Q3 2025 Financial Performance - Revenue reached $1,105 million, with a reported growth of +13% and organic growth of +12%[1] - Operating profit was $355 million[1] - Diluted earnings per share (EPS) stood at $3.40, reflecting a reported growth of +21% and comparable growth of +15%[1] - CAG (Companion Animal Group) revenue was $1,013 million, showing a reported growth of +14% and organic growth of +12%[1] - Water revenue reached $54 million, with a reported growth of +8% and organic growth of +7%[1] - LPD (Livestock, Poultry and Dairy) revenue was $34 million, demonstrating a reported growth of +17% and organic growth of +14%[1] 2025 Outlook - Revenue is projected to be between $4,270 million and $4,300 million, with a reported growth of 9.6% - 10.3% and organic growth of 8.8% - 9.5%[6,7] - Operating margin is expected to be 31.6% - 31.8%, with a reported margin expansion of 260 bps - 280 bps and comparable margin expansion of 80 bps - 100 bps[6,7] - EPS is forecasted to be $12.81 - $13.01, representing a reported growth of 20% - 22% and comparable growth of 12% - 14%[6,7] U.S. Companion Animal Practice Growth - As of September 30, 2025, U S total visits include clinical and non-clinical visits, there were an estimated ~330 million U S total visits in 2024[8,10] - Q3 2025 year-over-year growth in clinical visit was 2.0%[9] - Q3 2025 year-over-year growth in practice revenue was 4.5%[9]

Core Insights - IDEXX Laboratories raised its full-year profit and revenue forecasts following better-than-expected third-quarter results, indicating strong performance in the pet diagnostics sector [1] Financial Performance - The company reported improved third-quarter results compared to the previous year, which contributed to the upward revision of its profit and revenue forecasts [1] Market Trends - IDEXX Laboratories is capitalizing on the trend of pet owners increasing their spending on diagnostics and healthcare for their pets, reflecting a growing market demand [1]

Core Insights - IDEXX Laboratories, Inc. (IDXX) has updated its 2025 EPS outlook to a range of $12.81 - $13.01, reflecting a $0.33 increase at midpoint due to operational performance and tax rate benefits [1] - The company has revised its full year revenue growth guidance to $4.27 billion - $4.30 billion, indicating a reported growth of 9.6% - 10.3% [2] - For Q3, IDEXX reported earnings of $274.61 million, or $3.40 per share, a significant increase from $232.84 million, or $2.80 per share, in the previous year [3] Financial Performance - The updated EPS growth outlook is projected at 20% - 22% as reported and 12% - 14% on a comparable basis [1] - The company increased its outlook for organic revenue growth to 8.8% - 9.5%, marking an approximate 1% increase at midpoint [2] - Revenue for Q3 rose by 13.3% to $1.105 billion from $975.54 million year-over-year [3] Market Reaction - Shares of IDEXX are up 5% in pre-market trading following the earnings announcement [4]

Exhibit 99.1 IDEXX Laboratories Announces Third Quarter Results Third Quarter Performance Highlights Companion Animal Group ("CAG") CAG revenue growth was led by CAG Diagnostics recurring revenue growth of 11% as reported and 10% organic, including 18% reported and 14% organic gains in International regions, and 8% reported and organic growth in the U.S., outpacing sector growth levels. U.S. growth was aided by increased diagnostic frequency and an easing of clinical visit pressures. Additional U.S. compani ...

Earnings Report - IDEXX Laboratories, Inc. is set to release its third-quarter earnings results on November 3, with analysts expecting earnings of $3.14 per share, an increase from $2.80 per share in the same period last year [1] - The consensus estimate for quarterly revenue is $1.07 billion, compared to $975.54 million a year earlier [1] Recent Performance - On August 4, IDEXX Laboratories reported second-quarter financial results that exceeded expectations and raised its FY25 guidance above estimates [2] - Following the positive report, shares of IDEXX Laboratories rose by 0.2%, closing at $629.51 [2] Analyst Ratings - Stifel analyst Jonathan Block upgraded the stock from Hold to Buy, raising the price target from $640 to $700 [4] - UBS analyst Andrea Alfonso initiated coverage with a Neutral rating and a price target of $720 [4] - Morgan Stanley analyst Erin Wright maintained an Overweight rating and increased the price target from $722 to $765 [4] - Piper Sandler analyst David Westenberg maintained a Neutral rating and raised the price target from $510 to $700 [4] - JP Morgan analyst Chris Scott maintained an Overweight rating and increased the price target from $550 to $675 [4]

Earnings Report - IDEXX Laboratories, Inc. is set to release its third-quarter earnings results on November 3, with analysts expecting earnings of $3.14 per share, an increase from $2.80 per share in the same period last year [1] - The consensus estimate for quarterly revenue is $1.07 billion, compared to $975.54 million a year earlier [1] Recent Performance - On August 4, IDEXX Laboratories reported better-than-expected second-quarter financial results and raised its FY25 guidance above estimates [2] - Following the announcement, shares of IDEXX Laboratories rose 0.2% to close at $629.51 [2] Analyst Ratings - Stifel analyst Jonathan Block upgraded the stock from Hold to Buy, raising the price target from $640 to $700 [4] - UBS analyst Andrea Alfonso initiated coverage with a Neutral rating and a price target of $720 [4] - Morgan Stanley analyst Erin Wright maintained an Overweight rating and increased the price target from $722 to $765 [4] - Piper Sandler analyst David Westenberg maintained a Neutral rating and raised the price target from $510 to $700 [4] - JP Morgan analyst Chris Scott maintained an Overweight rating and increased the price target from $550 to $675 [4]

Earnings Reports - Williams Companies Inc (NYSE:WMB) is expected to report quarterly earnings of 51 cents per share on revenue of $2.89 billion [2] - Spirit AeroSystems Holdings Inc (NYSE:SPR) reported a loss of $4.87 per share with quarterly sales of $1.585 billion, missing the analyst consensus estimate of $1.923 billion [2] - Goodyear Tire & Rubber Co. (NASDAQ:GT) is anticipated to post quarterly earnings of 19 cents per share on revenue of $4.67 billion [2] - IDEXX Laboratories Inc. (NASDAQ:IDXX) is projected to report quarterly earnings of 3.13 per share on revenue of $1.07 billion [2] - ON Semiconductor Corp. (NASDAQ:ON) is expected to post quarterly earnings of 59 cents per share on revenue of $1.51 billion [2] Stock Performance - Williams shares rose 0.4% to close at $57.87 on Friday [2] - Spirit AeroSystems shares gained 1% to close at $36.69 on Friday [2] - Goodyear Tire shares rose 0.6% to $6.93 in after-hours trading [2] - IDEXX Laboratories shares rose 0.9% to $634.89 in after-hours trading [2] - ON Semiconductor shares gained 0.7% to $50.44 in after-hours trading [2]

Core Viewpoint - The article compiles significant research calls from Wall Street, highlighting upgrades for various companies based on their recent performance and outlook. Group 1: Company Upgrades - Jefferies upgraded Apple (AAPL) to Hold from Underperform with a price target of $246.99, up from $203.07, after September quarter revenue grew about 8% and gross margin came in at 47.2%, or about 0.5% better than expected including a $1.1B tariff [2] - Goldman Sachs upgraded Roblox (RBLX) to Buy from Neutral with a price target of $180, up from $155, following the Q3 earnings report, citing strength in bookings, revenue, and daily active user growth, with management optimistic about long-term scaling [2] - BTIG upgraded Unity (U) to Neutral from Sell and removed the prior $27 price target, noting healthy spending trends based on recent surveys of gaming and non-advertising professionals [2] - Piper Sandler upgraded Hershey (HSY) to Neutral from Underweight with an unchanged price target of $167, highlighting the company's plans to be "on-algorithm" in 2026 for better visibility [2] - Stifel upgraded Idexx Laboratories (IDXX) to Buy from Hold with a price target of $700, up from $640, expecting accelerated recurring revenue growth in the Companion Animal Group [2]

Core Viewpoint - Analysts expect Idexx Laboratories (IDXX) to report quarterly earnings of $3.14 per share, reflecting a year-over-year increase of 12.1%, with revenues projected at $1.07 billion, up 9.7% from the previous year [1]. Earnings Projections - The consensus EPS estimate has been revised upward by 0.5% in the last 30 days, indicating a reassessment of initial estimates by covering analysts [1][2]. Revenue Estimates - Revenue from the Companion Animal Group (CAG) is expected to reach $981.37 million, representing a 10% increase from the prior-year quarter [4]. - Revenue from Other segments is projected at $4.48 million, indicating a 1.8% increase year-over-year [4]. - Revenue from Livestock and Poultry Diagnostics (LPD) is estimated at $30.45 million, reflecting a 5% increase from the previous year [5]. - Water revenue is expected to be $54.46 million, showing an 8.6% increase year-over-year [5]. - Revenue from the Companion Animal Group in the United States is projected at $654.89 million, indicating an 8.4% year-over-year change [5]. - International revenue from the Companion Animal Group is estimated at $324.70 million, reflecting a 12.8% increase [6]. - LPD International revenue is expected to be $24.64 million, indicating a 5.1% increase [6]. - Water International revenue is projected at $26.02 million, reflecting a 10.7% increase [6]. Gross Profit Estimates - Gross Profit for the Companion Animal Group (CAG) is expected to reach 61.4%, up from 61.0% reported in the same quarter last year [7]. - Gross Profit for Other segments is projected at 26.2%, compared to 49.9% reported in the previous year [7]. - Gross Profit for LPD is expected to be 50.4%, slightly down from 50.5% reported last year [8]. - Gross Profit for Water is projected at 69.6%, up from 69.3% reported in the same quarter last year [8]. Market Performance - Shares of Idexx have experienced a -0.7% change in the past month, contrasting with a +3.8% move of the Zacks S&P 500 composite [8].

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Idexx Laboratories (IDXX) due to higher revenues, with a focus on how actual results will compare to estimates to influence stock price [1][2]. Earnings Expectations - Idexx is expected to report quarterly earnings of $3.14 per share, reflecting a year-over-year increase of +12.1%, with revenues projected at $1.07 billion, up 9.8% from the previous year [3]. - The earnings report is scheduled for release on November 3, and better-than-expected results could lead to a stock price increase, while disappointing results may cause a decline [2]. Estimate Revisions - The consensus EPS estimate has been revised 0.46% higher in the last 30 days, indicating a positive reassessment by analysts [4]. - The Most Accurate Estimate for Idexx is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +0.23%, suggesting a bullish outlook on earnings prospects [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive Earnings ESP reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [10]. - Idexx holds a Zacks Rank of 2, enhancing the likelihood of beating the consensus EPS estimate [12]. Historical Performance - Idexx has consistently surpassed consensus EPS estimates, achieving this in the last four quarters, including a +9.67% surprise in the most recent quarter [13][14]. Industry Context - In comparison, Edwards Lifesciences (EW) is expected to report earnings of $0.59 per share, indicating a year-over-year decline of -11.9%, with revenues projected at $1.5 billion, up 11.1% from the previous year [18]. - Edwards Lifesciences has a lower Earnings ESP of -1.22% and a Zacks Rank of 3, making it challenging to predict an earnings beat [19].